NasdaqCM:CORTPharmaceuticals
How FDA Relacorilant Setback and Legal Probes Will Impact Corcept Therapeutics (CORT) Investors
In late December 2025, Corcept Therapeutics received a Complete Response Letter from the U.S. FDA for its relacorilant NDA in hypertension secondary to hypercortisolism, with the agency requesting additional evidence of effectiveness and expressing concerns about the clinical program and study design.
The setback has triggered multiple shareholder law firm investigations into potential securities law violations, raising fresh questions about Corcept’s regulatory communication, risk...